[{"id":"626de316-d799-4804-9309-0166aa718911","acronym":"NCI-2018-01296","url":"https://clinicaltrials.gov/study/NCT02983578","created_at":"2021-01-18T14:40:40.387Z","updated_at":"2025-02-25T15:07:25.564Z","phase":"Phase 2","brief_title":"Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer","source_id_and_acronym":"NCT02983578 - NCI-2018-01296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • STAT3","pipe":" | ","alterations":" PD-L1 expression • STAT3 expression","tags":["CD8 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • STAT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/02/2017","start_date":" 03/02/2017","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-08-27"},{"id":"ffb136f1-6291-45e5-a40d-c7db3edb36d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986240","created_at":"2023-08-14T15:09:52.950Z","updated_at":"2024-07-02T16:34:27.038Z","phase":"Phase 1","brief_title":"Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS \u0026 AML","source_id_and_acronym":"NCT05986240","lead_sponsor":"Montefiore Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • danvatirsen (AZD9150)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/08/2024","start_date":" 05/08/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-12"},{"id":"e065d086-8c9a-4bc6-895e-ec02b787c8d1","acronym":"PEMDA-HN","url":"https://clinicaltrials.gov/study/NCT05814666","created_at":"2023-04-18T15:04:16.845Z","updated_at":"2024-07-02T16:34:59.660Z","phase":"Phase 2","brief_title":"Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC","source_id_and_acronym":"NCT05814666 - PEMDA-HN","lead_sponsor":"Flamingo Therapeutics NV","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • danvatirsen (AZD9150)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-05-31"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"b10fda2b-447e-4f1a-a80d-b097d7fb22c5","acronym":"MAGELLAN","url":"https://clinicaltrials.gov/study/NCT03819465","created_at":"2021-01-18T18:52:14.035Z","updated_at":"2024-07-02T16:35:17.376Z","phase":"Phase 1","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","source_id_and_acronym":"NCT03819465 - MAGELLAN","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 05/23/2023","primary_completion_date":" 05/23/2023","study_txt":" Completion: 03/26/2026","study_completion_date":" 03/26/2026","last_update_posted":"2024-02-28"},{"id":"34daa706-9096-4fce-9a76-dd0af1cf295c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01563302","created_at":"2021-01-18T06:37:34.260Z","updated_at":"2025-02-25T15:05:13.817Z","phase":"Phase 1/2","brief_title":"Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers","source_id_and_acronym":"NCT01563302","lead_sponsor":"Ionis Pharmaceuticals, Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e danvatirsen (AZD9150)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 02/27/2012","start_date":" 02/27/2012","primary_txt":" Primary completion: 03/23/2016","primary_completion_date":" 03/23/2016","study_txt":" Completion: 03/23/2016","study_completion_date":" 03/23/2016","last_update_posted":"2018-06-25"}]